AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 122 min read$REPL

Schwendenman Andrew sold $99K of REPL

Schwendenman Andrew (Chief Accounting Officer) sold 7,632 shares of Replimune Group, Inc. (REPL) at $12.97 on 2026-08-10.

Original reporting
SEC EDGAR · Schwendenman Andrew
Published Aug 12, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, total value, and post-transaction holdings). No operational or financial updates are provided.

02

Market read

Traders may note the insider sale as a small sentiment datapoint, but there is no fundamental catalyst in the filing.

03

What to watch

Insider sales can be scheduled around personal events and do not reflect forward-looking valuation unless paired with other disclosures (guidance changes, financing, litigation, or clinical/regulatory milestones).

Relevance 3/10Novelty 3/10Timing: filed Aug. 12, transaction dated Aug. 10

Background

The article is an SEC Form 4 insider transaction disclosure for Replimune Group, Inc.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune Group disclosed an insider open-market sale by CFO Andrew Schwendenman of 7,632 shares at $12.97 on Aug. 10.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a primary-source insider transaction, but it does not include new company performance, guidance, or regulatory/contract developments. The disclosed sale size is also relatively small versus typical market-moving thresholds.

Market effects

Sector

Minimal. Insider-sale Form 4s rarely reset sector expectations without accompanying company-specific news.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a 10b5-1 plan does not necessarily imply bearish intent; insiders may sell for diversification, taxes, or planned personal liquidity needs.

Key entities

  • issuer
    Replimune Group, Inc.

    Company whose insider transaction was disclosed on Form 4.

  • insider
    Schwendenman Andrew

    Chief Accounting Officer who sold 7,632 shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

REPL insider trading history →

Related articles

OCT 28
$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.

tradingview.com1 min
OCT 28
$REPLMed

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m.

SEC EDGAR 8-K2 min
OCT 1
$REPLHighAI 8/10

Replimune launches melanoma therapy in US market

Replimune Group Inc. (REPL) announced the U.S. commercial launch of TUDRIQEV, a melanoma therapy for advanced cutaneous melanoma patients who progressed on PD-1-blocking treatments. The FDA granted accelerated approval based on a 24.2% objective response rate in trials. The company estimates 105,000 new U.S. melanoma cases in 2025. Continued approval depends on confirmatory trial results.

investing.com2 min
OCT 1
$REPLHighAI 8/10

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

Replimune Group, Inc. (REPL) announced that TUDRIQEV™, a treatment for advanced melanoma, is now available in the U.S. The therapy, approved under accelerated approval, is indicated for adult patients who have progressed with PD-1-blocking antibody regimens. TUDRIQEV achieved a 24.2% objective response rate in clinical trials, with a median duration of 14.1 months. The company also launched a patient support program to assist with access and reimbursement.

globenewswire.com2 min